- Home
- KMI vs INM Comparison
KMI vs INM Comparison
Compare KMI & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KMI | INM |
|---|---|---|
| Founded | 1936 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.8B | 7.1M |
| IPO Year | 2010 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KMI | INM |
|---|---|---|
| Price | $31.76 | $1.40 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $33.69 | N/A |
| AVG Volume (30 Days) | ★ 11.0M | 68.0K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.74% | N/A |
| EPS Growth | 17.09 | ★ 62.68 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $16,937,000,000.00 | $4,942,633.00 |
| Revenue This Year | $5.43 | N/A |
| Revenue Next Year | $4.52 | N/A |
| P/E Ratio | $38.88 | ★ N/A |
| Revenue Growth | ★ 12.17 | 7.50 |
| 52 Week Low | $25.60 | $0.58 |
| 52 Week High | $34.81 | $2.50 |
Technical Indicators
Market Signals| Indicator | KMI | INM |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 50.75 |
| Support Level | $30.77 | $1.35 |
| Resistance Level | $32.94 | $1.40 |
| Average True Range (ATR) | 0.70 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 57.84 | 54.88 |
Price Performance
Historical ComparisonAbout KMI Kinder Morgan Inc.
Kinder Morgan operates natural gas, crude oil, and refined products pipelines connecting producing regions to demand centers. It is principally involved in the gathering, storage, and transmission of natural gas across the continental United States. It also operates distribution centers for refined products along with the largest fleet of Jones Act-compliant tankers.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.